 |
88 Diseases |  |
68 Trials |
|
68 Trials |  |
2888 News |  |
| «12...24252627282930313233343536 |
- | tacrolimus oral / Generic mfg., leflunomide / Generic mfg.
Trial termination: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients (clinicaltrials.gov) - Jul 16, 2013
P3, N=84, Terminated, Sponsor: Astellas Pharma Inc
Recruiting --> Terminated; Due to safety concern of active control drug
- | tacrolimus oral / Generic mfg., leflunomide / Generic mfg.
Enrollment change: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients (clinicaltrials.gov) - Jul 16, 2013
P3, N=84, Terminated, Sponsor: Astellas Pharma Inc
Recruiting --> Terminated; Due to safety concern of active control drug N=250 --> 84
- pateclizumab (RG7416) / Roche
Enrollment change, Combination therapy: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 21, 2013
P2, N=211, Completed, Sponsor: Genentech
N=250 --> 84 N=210210 --> 211
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Mar 18, 2013
P3, N=200, Recruiting, Sponsor: Sanofi
N=210210 --> 211 Not yet recruiting --> Recruiting
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies (clinicaltrials.gov) - Mar 10, 2013
P3, N=2068, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Initiation date: Aug 1929 --> Sep 2005
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Jan 13, 2013
P3, N=200, Recruiting, Sponsor: Sanofi
- ||| staphylococcal protein A (PRTX-100) / Protalex
New P1 trial, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 13, 2012
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
- New P4 trial: A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in low disease states in psoriatic arthritis (EUDRACT) - Dec 3, 2012
P4, N=30, Ongoing, Sponsor: University of Leeds
- || leflunomide / Generic mfg., azathioprine / Generic mfg.
New P3 trial: The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy (clinicaltrials.gov) - Nov 13, 2012
P3, N=158, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
- Enrollment open, MRI: Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study (clinicaltrials.gov) - Nov 10, 2012
P4, N=20, Recruiting, Sponsor: Singapore General Hospital
Initiation date: Aug 1929 --> Sep 2005 Active, not recruiting --> Recruiting
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) (clinicaltrials.gov) - Nov 7, 2012
P3, N=522, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) (clinicaltrials.gov) - Oct 16, 2012
P3, N=522, Recruiting, Sponsor: Sanofi
- leflunomide / Generic mfg.
Trial initiation date, Head-to-Head: Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=15, Completed, Sponsor: Chinese Academy of Sciences
Not yet recruiting --> Recruiting Initiation date: Jun 2012 --> Oct 2012
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Aug 27, 2012
P4, N=1, Completed, Sponsor: Pfizer
Initiation date: Jun 2012 --> Oct 2012 N=8227 --> 1
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Aug 27, 2012
P4, N=1, Completed, Sponsor: Pfizer
N=8227 --> 1 Enrolling by invitation --> Completed
- |||| Trial completion: Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse (clinicaltrials.gov) - Aug 20, 2012
P2, N=60, Completed, Sponsor: Pfizer
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: ROSE: A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Aug 12, 2012
P3, N=619, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P4 trial, MRI: Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study (clinicaltrials.gov) - Aug 5, 2012
P4, N=20, Recruiting, Sponsor: Singapore General Hospital
- Enbrel (etanercept) / Pfizer, Amgen
New P4 trial, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Jul 18, 2012
P4, N=1, Completed, Sponsor: Pfizer
- leflunomide / Generic mfg.
Enrollment change: A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications (clinicaltrials.gov) - Jul 5, 2012
P=N/A, N=1748, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed N=3496 --> 1748
- ||||| leflunomide / Generic mfg.
New P2 trial: An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria (clinicaltrials.gov) - Jun 13, 2012
P2, N=60, Recruiting, Sponsor: Changzheng-Cinkate
- leflunomide / Generic mfg.
Combination therapy: DCCT: Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research (clinicaltrials.gov) - Jun 10, 2012
P=N/A, N=500, Recruiting, Sponsor: Shanxi Medical University
- Zelboraf (vemurafenib) / Roche
New P1/2 trial, Combination therapy, Metastases: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma (clinicaltrials.gov) - Jun 3, 2012
P1/2, N=55, Suspended, Sponsor: Massachusetts General Hospital
- leflunomide / Generic mfg.
Clinical: A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications (clinicaltrials.gov) - May 15, 2012
P=N/A, N=1748, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute